drugset / Trial / NCT05824481
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus lenvatinib.
Timeline
- Start
- 2023-05-08
- Primary completion
- 2025-07-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Lenvatinib | Small molecule | 16 mg | Oral |